Peter John Nigro, MD | |
770 Sumneytown Pike, West Point, PA 19486 | |
(215) 652-7022 | |
Not Available |
Full Name | Peter John Nigro |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Occupational Medicine |
Location | 770 Sumneytown Pike, West Point, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1619191335 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | MD419200 (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Peter John Nigro, MD 536 Atsion Rd, Shamong, NJ 08088-9533 Ph: (609) 268-3687 | Peter John Nigro, MD 770 Sumneytown Pike, West Point, PA 19486 Ph: (215) 652-7022 |
News Archive
Bodycote, the world's largest heat treating services provider, is pleased to announce that its Derby, UK location is the first facility in Europe to earn the MedAccred accreditation underlining the high standards of quality achieved.
Poor oral health and hygiene are increasingly recognized as major risk factors for pneumonia among the elderly. To identify modifiable oral health-related risk factors, lead researcher Toshimitsu Iinuma, Nihon University School of Dentistry, Japan, and a team of researchers prospectively investigated associations between a constellation of oral health behaviors and incidences of pneumonia in the community-living of elders 85 years of age or older.
How do mammals keep two biologically crucial metabolites in balance during times when they are feeding, sleeping, and fasting? The answer may require rewriting some textbooks.
New parents often expect their baby to start sleeping through the night by around six months of age. Indeed, they often receive messages from pediatricians and others about the importance of early sleep consolidation.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported results through month 36 of the completed FAMEā¢ Study.
› Verified 6 days ago